# Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)

> **NCT05218668** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Woolsey Pharmaceuticals** · enrollment: 40 (estimated)

## Conditions studied

- Amyotrophic Lateral Sclerosis

## Interventions

- **DRUG:** Fasudil (WP-0512)
- **DRUG:** Fasudil (WP-0512)

## Key facts

- **NCT ID:** NCT05218668
- **Lead sponsor:** Woolsey Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-12-22
- **Primary completion:** 2026-07
- **Final completion:** 2029-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05218668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05218668, "Rho Kinase Inhibitor in Amyotrophic Lateral Sclerosis (REAL)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05218668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*